Smart Publications Update                                                              Page 9  
  1. EDTA Chelation: A Misunderstood Therapy for Atherosclerosis and Other Diseases, by Ward Dean, MD, August 1997, VRP Library, www.vrp.com.

    2.
  2. Parisi AF, Folland ED, Hartigan PA. Comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. N Engl J Medl 992;326:1O-16.
  3. Edmunds LH, Stephenson LW, Edie RN, Ratcliffe MB. Open-heart surgery in octogenarians. N Engl J Med. 1988;319:131-136
  4. CASS Prlncipal investigators and the Associates. Goronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery: Survival data. Circulation. 1983; 68: 939-950.
  5. Arom KV, Cohen DE, Strobl FT. Effect of intraoperative intervention on neuroIogical outcome based on electroencephalographic monitoring during cardiopulmonary bypass. Ann Thorac Surg. 1988; 48:476-483.
  6. CASS Principal Investigators and the Associates. Myocardial infarction and mortality in the Coronary Artery Surgery Study randomized trial. N Engl J Med.1984; 310:750-758.
  7. Center for Disease control website: http://www.cdc.gov
  8. Cranton, Elmer. Bypassing Bypass (2d Ed). Medex Publishers, Trout Dale, VA 24378-0044, 1992.
  9. EDTA Chelation: A Misunderstood Therapy for Atherosclerosis and Other Diseases, by Ward Dean, MD, August 1997, VRP Library, www.vrp.com.
  10. Harman, D. The biologic clock: The mitochondria? J Am Geriatr Soc, 1972, 20:145-147.
  11. EDTA Chelation: A Misunderstood Therapy for Atherosclerosis and Other Diseases, by Ward Dean, MD, August 1997, VRP Library, www.vrp.com.
  12. Clarke NE, Clarke CN, Mosher RE. Treatment of angina pectoris with disodium ethelyne diamene tetraacetic acid. Am J Med Sci. 1956: December: 654-666.
  13. Meltzer LE, Ural E, Kitchell JR. The treatment of coronary artery heart disease with disodium EDTA. In: Seven M, ed. Metal-Binding in Medicine, Philadelphia: JB Lippincott: 196
  1. These papers, The correlation between EDTA Chelation Therapy and improvement in cardiovascular function: A Meta -Analysis, and EDTA Chelation Treatment for vascular disease: A Meta-Analysis using unpublished data, both by L.T. Chappell and J.P. Stahl, were published in the Journal of Advancement in Medicine in 1993 and 1994.
  2. Hancke, C. and Flytlie, K, Benefits of EDTA Chelation Therapy in Arteriosclerosis: A retrospective study of 470 patients, Journal of Aduancement in Medicine, 1993, 6:3,161-171.
  3. Olszewer E, Carter JP. EDTA chelation therapy in chronic degenerative disease. Med Hypotheses. 1988; 27:41-49.
  4. Olszewer E, Sabbag FC, Carter JP. A pilot double-blind study of sodiummagnesium EDTA in peripheral vascuIar disease .J Natl Med ASSOC. 1990; 82:173-174.
  5. Hancke C, Flytie K. Benefits of EDTA chelation therapy on arteriosclerosis. J Adv Med. 1993; 6:161 -172.
  6. Chappell LT, Janson M. EDTA chelation therapy in the treatment of vascular disease. J Cardiovasc Nurs. 1996; 10:78-86.
  7. Perry, H. Mitchell, Schroeder, Henry A. Depression of cholesterol levels in human plasma following ethylenediamine tetracetate and hydralazine. j Chronic Diseases, 1955, 2: 5, 520-532.
  8. Schroeder, Henry A. A practical method for the reduction of plasma cholesterol in man. J Chronic Diseases, 1956, 4: 461 -468.
  9. Perry, Jr., and Camel, G., Some effects of CaNa2EDTA on plasma cholesterol and urinary zinc in man, in: Metal Binding in Medicine, by Marvin J. Seven and L. Audrey Johnson (eds), 1960, J.B. Lippincott Company, Philadelphia,
    209-215.
  10. Born, G.R., and Geurkink, T.L. Improved peripheral vascular function with low dose intravenous ethylene diamine tetraacetic acid (EDTA). Townsend Letter for Doctors. July, 1994, # 132, 722-726

To find a doctor qualified to provide you with IV chelation treatments, contact tne ACAM (American College for Advancement in Medicine) at:

ACAM . 23121 Verdugo Dr., Ste. 204 . Laguna Hills, CA 92653 . 800 532 3688 . www.acam.org

You can also check the web site of Smart Publications for other pointers on finding a physician. See www.smart-pubIications.com

EDTA Chelation therapy appears to be extremely safe, but as with almost any drug or supplement, there are potential adverse effects of EDTA chelation. One danger is nephrotoxicity (kidney damage). This is dependent on the dose, the rate of infusion, the patient's kidney function, and the patient's body burden of toxic heavy metals. Kidney damage was not uncommon in the early days of chelation therapy, when doses of EDTA in the range of 5-10 grams per day were used, and treatments were administered as often as 5 days per week.

Kidney damage can be easily prevented, however, by carefully adjusting the frequency, dose and rate in which the EDTA is administered. In addition, judicious administration of EDTA over prolonged periods (three to six months and longer) actually improves kidney function.

 Other potential aaverse enects include hypocalcemia (excessively low blood levels of calcium) due to EDTA's binding excessively with calcium in the blood, hypoglycemia (low blood sugar), believed to be due to accompanying hypocalcemia, and phlebitis (inflammation of the vein), usually due to improperly prepared solutions. Rarely reported side effects include chills and fever following infusion, acerbation of congestive heart failure due to fluid overload, fatigue (usually due to hypoglycemia or hypocalcemia), seizures, arrhythmias, or rash. The risk of incurring any of the above adverse effects has further been greatly reduced by the recent finding of Drs. Grant Born and Tammy Geurkink23 that even greater benefit can be obtained by most patients who are treated with only 1.5 grams of EDTA per treatment, rather than with the standard dose of three grams. (But this refers to the IV infusion of EDTA, not to be confused with dosages for oral use, which are in the range of 500mg to 4000mg per day.)

http://www.smart-publications.com SMART PUBLICATIONS UPDATE
9

Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14